A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir Twice-Yearly in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

The goal of this clinical study is to compare how effective a long-acting treatment of injectable combination of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) is versus continuing a daily oral HIV treatment in adults with HIV-1 whose virus is already well controlled, after 1 year (52 weeks) of treatment.
The primary objective of this study is to evaluate the efficacy of switching to the regimen of LEN, TAB, and ZAB versus continuing an oral stable baseline regimen (SBR) in virologically suppressed people with HIV-1 (PWH) as determined by the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52.

开始日期2026-07-01

申办/合作机构

Gilead Sciences, Inc.

NCT07682961

/ Not yet recruiting临床3期

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment, after 1 year (52 weeks) of the treatment.
The primary objective of this study are to evaluate the efficacy of switching to the regimen of LEN, TAB, and ZAB versus switching to CAB and RPV in virologically suppressed people with HIV-1 (PWH) as determined by the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52.

开始日期2026-07-01

申办/合作机构

Gilead Sciences, Inc.

NCT07054931

/ Recruiting临床2期IIT

AbVax: Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV to Induce a Protective T-cell 'Vaccinal Effect' - a Randomised Phase II Clinical Trial

There is no cure for HIV infection. Antiretroviral therapy (ART) is widely available but requires daily, life-long intake. This can cause issues around side-effects, resistance, adherence and stigma. A new therapy, broadly neutralising antibodies, (bNAbs), may work as well as ART and may last longer - one dose can last six months. bNAbs appear to first target HIV viruses, then drive a protective immune response conferring long-term control, called the vaccinal effect. AbVax is a clinical trial to understand this effect and how to enhance it to give the strongest possible long-term protection for people living with HIV (PWH). The investigators are studying whether a combination of vaccines that attack HIV, a short period of treatment interruption induced viraemia (TIIV - stopping ART for a few weeks to allow a small amount of virus to return to the bloodstream) and bNABs will produce the most sustained immune protection.

开始日期2025-09-05

申办/合作机构

University of Oxford

100 项与 Teropavimab 相关的临床结果

登录后查看更多信息

100 项与 Teropavimab 相关的转化医学

登录后查看更多信息

100 项与 Teropavimab 相关的专利（医药）

登录后查看更多信息

项与 Teropavimab 相关的文献（医药）

2026-05-01·Lancet HIV

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial

Article

作者: Sutherland, Rebecca ; Uriel, Alison ; Ackerman, Margaret E ; Elliott, Tamara ; Loes, Sabine Kinloch-de ; Weiner, Joshua A ; Ujetz, Jacquie ; Fumagalli, Marcilio ; Gohil, Jesal ; Cherrill, Louise-Rae ; Tipoe, Timothy ; Lee, Ming J ; Caskey, Marina ; Fletcher, Stephen ; Frater, John ; Pett, Sarah ; Bittar, Cintia ; Box, Hanna ; Nussenzweig, Michel C ; Falaschetti, Emanuela ; Hamzah, Lisa ; Clarke, Amanda ; Seaton, Kelly E ; Nielsen, Henrik ; Brown, Helen ; Zacharopoulou, Panagiota ; Altaf, Mohammed ; Tomaras, Georgia D ; Søgaard, Ole S ; Taylor, Graham P ; Gunst, Jesper Damsgaard ; Fidler, Sarah ; Ring, Kyle ; Mangawa, Irvine ; Orkin, Chloe ; Fox, Julie ; Horowitz, Jill ; Godakandaarachi, Piyumika ; Collins, Simon ; Robinson, Nicola ; Boffito, Marta ; Cicconi, Paola ; Jahan, Ishrat ; Whitlock, Gary ; Kaczynska, Anna

BACKGROUND:

HIV-specific broadly neutralising antibodies (bNAbs) can maintain viral control after interrupting antiretroviral therapy (ART). We investigated the duration and efficacy of Fc-engineered long-acting bNAbs (LS-bNAbs) in maintaining ART-free HIV control compared with placebo.

METHODS:

RIO is a double-blind, randomised, placebo-controlled trial. Eligibile participants were adults age 18-60 years, initiated on ART in early-stage HIV infection, virally suppressed on ART, and had no evidence of viral insensitivity to 10-1074. Participants were randomly assigned (1:1) to receive two LS-bNAbs (3BNC117-LS and 10-1074-LS) in arm A or saline placebo in arm B; participants and study staff were masked to assignment. Eligible participants interrupted ART after receiving blinded intravenous infusions of either bNAbs or placebo. A second optional infusion was offered after 20 weeks for participants who remained virally suppressed without ART. The primary outcome was time to viral rebound 20 weeks after ART interruption, defined as either the first of six consecutive plasma HIV RNA measurements greater than 1000 copies per mL, or two measurements greater than 100 000 copies per mL. All randomly assigned participants were included in the analyses. This study is registered with ClinicalTrials.gov, NCT04319367.

FINDINGS:

68 participants were randomly assigned, 34 to each arm. By week 20, viral rebound had occurred in eight participants in arm A and 30 in arm B; 75% (95% CI 61-92) of participants in arm A did not have viral rebound, compared with 11% (4-29) of participants in arm B. Participants in arm A were 91% less likely to rebound than were those in arm B (hazard ratio 0·09; 95% CI 0·04-0·21, p<0·0001). There were 326 adverse events in arm A and 260 in arm B, including 19 treatment-related or procedure-related adverse events in arm A and 41 in arm B. Of nine serious adverse events, none were treatment-related. The most commonly reported treatment-related or procedure-related adverse events were fatigue, lethargy, or somnolence: 11 in arm A and nine in arm B. There were two severe adverse events (anal abscesses) possibly related to the study protocol, both in the placebo arm.

INTERPRETATION:

Long-acting bNAbs can sustain extended ART-free viral control in people treated during early-stage HIV and represent a promising step towards achieving ART-free HIV remission.

FUNDING:

Gates Foundation.

2026-04-21·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies in vivo

Article

作者: Cohn, Lillian B. ; Caskey, Marina ; Clyde, Abigail E. ; Romero, Elena V. ; Giorgi, Elena E. ; Taylor, Megan L. ; Feder, Alison F. ; Westfall, Dylan H. ; Azam, Walker

Broadly neutralizing antibodies (bNAbs) show promise for HIV treatment and prevention, but are vulnerable to resistance evolution. Comprehensively understanding in vivo viral escape from individual bNAbs is necessary to design bNAb combinations that will provide durable responses. We characterize viral escape from two such bNAbs, 10-1074 and 3BNC117, using deep, longitudinal sequencing of full-length HIV envelope ( env ) genes from study participants treated with bNAb monotherapy. Improved sequencing depth and computational evolutionary analyses permit us to identify in vivo routes and parallelism underlying HIV escape from each bNAb, providing insight into this evolutionary process. We find that 10-1074 escape is restricted to a small number of previously documented pathways seen across participants, but these escape mutations 1) emerge via extensively recurrent mutation, 2) are not equally preferred, and 3) can preexist at low frequency in intrahost viral populations before therapy, although their detection does not predict rebound timing. In contrast, 3BNC117 escape follows background-specific patterns in which specific escape mutations present in one intrahost population rarely emerge or spread in other populations, except among highly related viruses. Despite this, 3BNC117 escape mutations can still emerge recurrently within their host. Our findings map longitudinal in vivo antibody escape across 20 diverse clade B HIV intrahost populations and reveal clinically relevant resistance dynamics that highlight how combination bNAb therapies will need to contend with extensively recurring escape mutations and dependence on genetic background.

2026-02-01·Lancet Microbe

Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study

Article

作者: Brunetta, Jason ; Ogbuagu, Onyema ; Collins, Sean E ; VanderVeen, Laurie A ; Zhang, Nan ; McMahon, James H ; Morales-Ramirez, Javier O ; Baeten, Jared M ; Gaur, Aditya ; Gorgos, Linda ; Eron, Joseph ; Mponponsuo, Kwad ; Huang, Hailin ; Workowski, Kimberly

BACKGROUND:

In a phase 1b study (NCT04811040), lenacapavir combined with the broadly neutralising antibodies (bNAbs) teropavimab and zinlirvimab maintained virological suppression (HIV-1 RNA <50 copies per mL) for 6 months in people with HIV-1 highly susceptible to both bNAbs. This phase 2 study evaluated the efficacy and safety of switching to twice-yearly lenacapavir, teropavimab, and zinlirvimab versus continuing an oral stable baseline regimen (SBR) of antiretroviral therapy (ART). Here, we report the week-26 primary efficacy endpoint results.

METHODS:

This randomised, open-label, phase 2 study was conducted at 34 clinical sites across Australia, Canada, and the USA. People with HIV-1 RNA who had less than 50 copies per mL on oral ART with HIV-1 highly susceptible to bNAbs teropavimab and zinlirvimab (90% inhibitory concentration ≤2 μg/mL) were randomly assigned (2:1) to receive subcutaneous lenacapavir 927 mg (plus oral loading) combined with intravenous teropavimab 2550 mg and zinlirvimab 2550 mg twice-yearly (combined treatment group), or to continue an oral SBR (SBR group). Efficacy and safety analyses included participants who received at least one complete dose of the lenacapavir, teropavimab, and zinlirvimab or SBR. The primary endpoint was the proportion of participants with HIV-1 RNA concentration of 50 copies per mL or higher at week 26. Secondary endpoints included week-26 change from baseline in CD4 cell count and safety. This study is registered with ClinicalTrials.gov, NCT05729568, and is ongoing.

FINDINGS:

Between May 15, 2023, and Jan 2, 2024, of 241 participants screened, 80 were enrolled. At week 26, one (1·9%; 95% CI 0·0-10·1) of 53 participants receiving twice-yearly lenacapavir, teropavimab, and zinlirvimab and zero (95% CI 0·0-12·8) of 27 participants continuing SBR had HIV-1 RNA concentration of 50 copies per mL or higher; one participant per group had no virological data (US Food and Drug Administration Snapshot Algorithm). Excluding subcutaneous lenacapavir-related injection site reactions (n=33, predominantly grade 1), treatment-emergent adverse events occurred in 36 (68%) and 17 (63%) participants in the lenacapavir, teropavimab, and zinlirvimab group and SBR group, respectively. No infusion-related reactions to bNAbs, study drug-related grade 3 or worse adverse events, serious adverse events, deaths, or adverse events leading to discontinuation occurred in the lenacapavir, teropavimab, and zinlirvimab group.

INTERPRETATION:

A single administration of lenacapavir, teropavimab, and zinlirvimab in the study population demonstrated similar efficacy to daily oral ART through to week 26. This regimen was well tolerated, with no serious adverse events, supporting its potential as the first complete twice-yearly, long-acting, injectable HIV-1 treatment.

FUNDING:

Gilead Sciences.

项与 Teropavimab 相关的新闻（医药）

2026-07-05

·生物技术小编

工程化B细胞疗法（4大技术路线）

与清除 B 细胞的 CD19 CAR-T、抗 CD20 单抗完全相反：工程化 B 细胞是保留、改造、利用健康B细胞，通过基因编辑 / 病毒转染重编程自体B细胞，回输后依靠 B 细胞天然生物学特性发挥治疗作用。B 细胞独有优势超高蛋白分泌能力浆细胞每秒可分泌数千分子抗体 / 蛋白，远超普通体细胞；超长体内存续骨髓长效浆细胞、记忆 B 细胞可存活数年至数十年，实现一次输注长期给药；天然扩增开关接种对应抗原即可诱导工程化 B 细胞克隆扩增，提升药物浓度；低预处理需求多数管线无需重度清淋化疗，安全性显著优于 CAR-T。四大主流技术路线路线 1：分泌治疗性抗体的B细胞（最领先，已进入临床试验）原理 CRISPR 精准敲入 IgH 免疫球蛋白重链位点，替换天然抗体可变区，强制细胞持续分泌单克隆中和抗体 / 广谱中和抗体 bnAb；抗原刺激后分化为长效浆细胞，长期释放入血。适应症与管线感染性疾病 HIV 功能性治愈：插入广谱中和抗体（VRC01、3BNC117 等），灵长类动物已验证持续数年抗体滴度，抑制病毒反弹，2026 多团队推进 IND 申报；新冠、疟疾、RSV：一次性改造替代长期抗体注射；自身免疫病分泌中和自身抗体的拮抗性抗体，阻断自身抗原损伤；罕见病 / 肿瘤被动免疫临床代表管线 Immusoft ISP-001：改造 B 细胞分泌 α-L - 艾杜糖醛酸酶，治疗黏多糖贮积症 I 型，无需清淋，安全性良好，持续酶活性表达； Be Biopharma BE-101：CRISPR 编辑 B 细胞分泌凝血因子 IX，用于血友病 B，已完成临床给药（ NCT06611436）。路线 2：CAR-B 细胞（CAR 修饰 B 细胞，肿瘤 / 自免方向，临床前）杀伤型 CAR-B CAR 靶向肿瘤抗原，B 细胞通过 ADCC、补体通路杀伤肿瘤；同时可呈递抗原激活 T 细胞，弥补实体瘤免疫抑制微环境短板。短板：B 细胞本身细胞毒能力弱，单独疗效有限，主流策略为CAR-B+CAR-T 联合。调节型 CAR-B CAR 识别自身抗原，诱导 B 细胞分泌 IL-10、TGF-β 等抑炎因子，特异性抑制自身反应 T/B 细胞；用于重症狼疮、硬皮病、器官移植排斥，无全身性免疫抑制副作用。路线 3：抗原呈递工程化 B 细胞肿瘤疫苗（实体瘤热门方向）改造 B 细胞稳定表达肿瘤新抗原、共刺激分子（CD80/CD86），体外扩增回输。 B 细胞天然高表达 MHC I/II，强效交叉呈递；诱导持久记忆 CD8+T 细胞，解决树突状细胞疫苗扩增难、体内存续短的痛点；适配肺癌、黑色素瘤、结直肠癌等实体瘤，全部处于临床前 / 类器官验证阶段。路线 4：基因编辑调节性 B 细胞（Breg 疗法，移植 / 重度炎症）天然 Breg 数量极少，体外分离扩增 + 基因强化抑炎通路（IL-10 过表达）：抑制异体排斥、移植物抗宿主病 GVHD；对比调节性 T 细胞（Treg）：扩增更容易、体内稳定性更高、不诱发免疫耗竭；局限：标准化扩增工艺不成熟，无人体临床数据。两大基因改造技术平台1. CRISPR 定点敲入（主流长效方案）靶向 IgH 位点同源定向修复（HDR）优势：定点整合、拷贝数可控、持续稳定表达、无随机插入风险；短板：原代 B 细胞 HDR 编辑效率偏低（人体外周 B 细胞 5%–15%），体外扩增损耗细胞；优化方案：AAV6 提供修复模板 + RNP 核糖核蛋白递送，大幅提升编辑效率。2. 慢病毒 / AAV 随机转染（简易快速方案）病毒携带治疗基因随机整合 / 游离表达编辑效率高、操作简单、成本更低；风险：随机插入存在潜在致瘤风险，表达稳定性弱于定点敲入。参考资料 B Cell-Directed Therapy in Autoimmunity， Annu Rev Immunol. 2024 Jun;42(1):103-126. doi: 10.1146/annurev-immunol-083122-044829. https://be.bio/be-bio-announces-first-participant-dosed-in-become-9-trial-of-be-101-in-hemophilia-b/ https://www.immusoft.com/2024/09/23/immusoft-to-announce-positive-phase-1-data-for-first-engineered-b-cell-therapy-in-a-clinical-trial/

2026-07-04

·松鼠De小木屋

洛克菲勒大学最新研究：已锁定HIV针对长效中和抗体的100余种耐药突变

近日，洛克菲勒大学的科学家们在《自然·微生物学》上发表了一项名为《HIV-1毒株逃避广谱中和抗体的途径多种多样》的重要研究。他们通过成千上万次实验，摸清了HIV病毒是如何对“广谱中和抗体（bNAbs）”这种新疗法产生抗药性（耐药性）的。结果发现，大部分病毒株挺“聪明”的，有时候只要改变一个微小的氨基酸就能躲开抗体的围剿。这项研究的意义在于：它没有停留在“抗体有效”的表面，而是帮科研人员提前摸清了病毒的逃跑路线。这样一来，未来的药物就能通过“多抗体联手”的方式，把病毒的逃跑路线彻底堵死，从而开发出更长效、更不容易耐药的鸡尾酒疗法。广谱中和抗体在聊这项新研究之前，咱们先说个大家都很关心的前沿技术——广谱中和抗体（简称 bNAbs）。现在大家普遍用的抗逆转录病毒药物（ART），虽然效果很好，但最大的麻烦就是得天天吃、不能断。而广谱中和抗体（bNAbs）则是科学家从一部分自带“免疫超能力”的感染者（大约占1%~5%）体内提取出来的特殊抗体。这种抗体很厉害，能精准识别并锁死绝大多数的HIV毒株。在最近的临床试验里，研究人员让患者停掉传统的口服药，只打了一针包含两种bNAbs的针剂。结果挺让人振奋：一部分人 bullet 保持了长达20周的“查不到病毒载量”，还有三分之一的人甚至维持了大约一年。这就让大家看到了一种可能：未来我们是不是可以告别天天吃药，换成几个月甚至一年打一次针就行？为什么HIV能逃过抗体？想法很美好，但HIV病毒可不是个省油的灯。大家都知道，HIV最大的特点就是变异极快、版本极多。你研发出一种抗体去抓它，它在复制的过程中就会悄悄“变身”，让抗体认不出来，这就是医学上说的抗药性（耐药性）。为了弄清楚病毒到底是怎么变身的，洛克菲勒大学的 Paul Bieniasz 和 Theodora Hatziioannou 两位教授带队做了一场超级大实验。他们把全球各地的15种主要HIV毒株拿进实验室，模拟了成千上万次病毒遇到抗体（3BNC117 和 10-1074 这两种主流抗体）的场景。结果发现，病毒的逃跑门槛其实挺低的： “单点变身”就够了：在面对 3BNC117 抗体时，15种病毒里有12种仅仅改变了一个“氨基酸”（相当于换了一颗螺丝钉），就成功让抗体失效了。而在面对 10-1074 抗体时，所有测试的病毒更是全员通过这种简单变身轻松逃脱。意想不到的盲区：科学家还发现，有时候病毒变异的地方，根本不在抗体直接攻击的区域，但它就是能产生远程联动，让抗体抓不住。这在以前的科研里是没人预料到的。第一作者 Alex Stabell 医生直言：“让人有些惊讶的是，对大多数HIV毒株来说，想逃开这些特殊抗体其实挺容易的。” 别担心，这反而是个好消息看到这里你可能会想：那这个新疗法是不是要凉了？恰恰相反。医学研究就像打仗，不怕敌人变异，就怕不知道敌人往哪儿变。这项研究最大的贡献，就是把病毒能想到的、所有的变身方法（100多种突变路径）全部列成了一张“病毒逃跑路线图”。 Bieniasz 教授解释说，知道了不同毒株对不同抗体的反应，医生以后就能做“精准医疗”——在用药前先看看你体内的病毒属于哪种版本，有没有耐药风险。更重要的是，这项研究为未来的“多抗体鸡尾酒疗法”指明了方向。虽然病毒改变一个氨基酸能逃过一种抗体，但如果科学家把两三种不同的广谱中和抗体组合在一起（它们分别攻击病毒不同的部位），病毒就傻眼了。因为这意味着它得同时改变好多个地方才能逃脱，这在概率上几乎是不可能的。用专业术语来说，这叫提高“基因壁垒”。现在的药物研发目标，不再是只追求短期的病毒压制，而是要筑起一道足够高的墙，让病毒怎么变异也翻不过去。目前，这个科研团队正在用同样的方法，去测试更多的抗体组合。对我们感染者来说，前沿科学每往前走一步，未来的治疗方案就会更轻松、更安全。我们不需要去焦虑病毒的狡猾，因为科学界正在以更快的速度，帮我们把防线筑得更稳固。文章标题：Diverse paths to broadly neutralizing antibody escape among HIV-1 strains. 作者：Stabell, A.C., Lee, S., Park, D.J. et al. DOI：10.1038/s41564-026-02347-x 编译：松鼠哥【转载声明】本文内容版权归作者所有，未经授权不得转载。如需转载请后台联系小编，获取转载许可。【医疗声明】本文章内容仅供参考，不能替代专业医疗建议。如有任何健康问题或疑虑，请及时咨询医生或其他专业医务人员。

2026-05-12

·生物谷

Nat Microbiol：HIV的“逃生术”被拆穿，广谱中和抗体为何失效有了答案

研究开发了一套名为RISC的高通量筛选方法，在15株覆盖全球HIV-1遗传多样性的病毒株中，并行开展了7776组选择实验，系统绘制了针对两种明星广谱中和抗体的耐药突变图谱。全球范围内，HIV-1感染依然是一个沉重的公共卫生负担，尽管抗病毒药物能够有效抑制病毒复制，但患者需要每日服药，一旦停药，病毒很快就会卷土重来。广谱中和抗体的出现曾带来新的希望：只需一次注射，就能让病毒在数月内保持“隐身”状态，在一项近期临床研究中，接受两种广谱中和抗体治疗的部分感染者，病毒载量维持了长达20周几乎检测不到的水平，其中一人甚至持续了约一年。然而，HIV-1的遗传多样性之高、变异速度之快，在整个病毒界都堪称“佼佼者”，它能迅速对中和抗体产生耐药性，这意味着抗体疗法的长期有效性面临巨大挑战，究竟哪些突变能让HIV-1从抗体的“围剿”中逃脱？不同的病毒株是否存在通用的逃生路线？这些问题一直缺乏系统性答案。日前，发表在国际杂志Nature Microbiology上题为“Diverse paths to broadly neutralizing antibody escape among HIV-1 strains”的研究报告中，来自洛克菲勒大学等机构的科学家们通过研究给出了迄今为止最全面的解答，文章中，他们开发了一套名为RISC的高通量筛选方法，在15株覆盖全球HIV-1遗传多样性的病毒株中，并行开展了7776组选择实验，系统绘制了针对两种明星广谱中和抗体（3BNC117和10-1074）的耐药突变图谱。在一组多样化的 HIV-1 毒株中筛选对3BNC117或10-1074的耐药性这项研究的第一个关键发现是：大多数HIV-1病毒株逃避抗体打击的门槛低得惊人。对于3BNC117，15株病毒中有12株仅需单个氨基酸位点改变，就足以使抗体的半抑制浓度飙升到治疗无效的水平。而对于10-1074，所有测试的9株病毒同样只需一个突变就能成功逃逸。换句话说，对于大部分流行毒株，抗体想要“一网打尽”几乎不可能，病毒稍作“变脸”就能轻松过关。但并非所有病毒都如此“好对付”，研究中也发现了少数毒株，它们需要多个氨基酸同时突变，或者借助一些非典型的复杂机制才能获得耐药性，这意味着不同病毒株对广谱中和抗体的“遗传屏障”高低不一。那些需要付出更大“代价”才能逃逸的毒株，恰恰是联合抗体疗法最理想的靶标。更出人意料的是，大量的耐药突变并不位于抗体原本识别的病毒包膜表位区域，以3BNC117为例，它靶向的是CD4结合位点，但许多突变发生在完全不相干的部位；这些“远程突变”如何影响抗体的中和效果，目前尚无法通过常规结构预测，这一发现提示，抗体逃逸的途径远比想象中复杂，仅凭表位分析远远不够。研究人员还发现，某些针对3BNC117产生的耐药突变，竟然能同时导致针对其他不同表位的广谱中和抗体也失效；这种交叉耐药现象意味着，如果不加选择地随意组合抗体，可能出现“按下葫芦浮起瓢”的窘境。这项研究并非在宣布某种新疗法诞生，而是为合理设计抗体组合提供了关键的地图，知道病毒最怕什么、最容易从哪里突破，才能选出那些“逃生难度最大”的抗体组合。正如研究者所言，HIV-1变异极快，人群中已有的多样性已经相当庞大，多药联合是早已被验证的有效策略。但联合的前提是，必须知道哪些药物组合能真正筑起一道高遗传屏障。该研究建立的高通量筛选平台，未来还可用于评估其他广谱中和抗体及其组合从而为临床选择最优方案提供实验依据，对于长期与HIV共存的感染者而言，这项研究带来的不是立即可用的新药，而是一个更清晰的终点：那些曾经让人充满希望、却又屡屡失效的抗体，终于有了被科学驾驭的可能。（生物谷Bioon.com）参考文献： Stabell, A.C., Lee, S., Park, D.J. et al. Diverse paths to broadly neutralizing antibody escape among HIV-1 strains. Nat Microbiol (2026). doi：10.1038/s41564-026-02347-x

疫苗临床1期

100 项与 Teropavimab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床3期	-	Gilead Sciences, Inc.	2026-07-01
获得性免疫缺陷综合征	临床2期	中国	前沿生物药业（南京）股份有限公司	2021-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04319367 (RIO, Pubmed \| Lancet HIV)	临床1/2期	HIV感染	68	3BNC117-LS and 10-1074-LS	窪齋膚顧夢願鬱積獵築(觸鬱憲築範鏇壓網簾製) = There were 326 adverse events in arm A and 260 in arm B, including 19 treatment-related or procedure-related adverse events in arm A and 41 in arm B. Of nine serious adverse events, none were treatment-related. The most commonly reported treatment-related or procedure-related adverse events were fatigue, lethargy, or somnolence: 11 in arm A and nine in arm B. There were two severe adverse events (anal abscesses) possibly related to the study protocol, both in the placebo arm. 衊蓋築膚膚衊鏇遞製鏇 (夢窪壓糧餘鏇觸夢淵鹽 ) 更多	积极	2026-05-01
				Saline placebo
NCT05729568 (Pubmed \| Lancet Microbe)	临床2期	HIV感染	80	Lenacapavir+Teropavimab+Zinlirvimab	積觸鏇蓋製憲積築壓鑰(願齋觸淵襯積廠製顧顧) = 鹽窪網鬱壓糧獵壓齋鑰窪糧製壓鏇餘糧鹽簾願 (鏇鹹夢鬱鹹網積憲蓋鹽 )	积极	2026-02-01
				SBR	齋淵顧網繭淵鏇願鏇憲(鑰積糧鑰餘襯觸願餘鹽) = 艱鏇網構憲網製窪鏇獵齋糧衊築淵艱齋鹽遞餘 (蓋衊築憲遞醖願選鏇觸, 0.0 ~ 12.8) 更多
NCT05729568 (CTgov)	临床2期	HIV感染	83	Antiretroviral Therapy	積夢憲繭鏇餘醖廠憲餘 = 夢鏇醖醖築鏇顧憲構憲襯遞網鑰鬱鑰艱觸願蓋 (襯壓膚鹽衊製繭齋衊顧, 積製製糧膚鑰蓋壓獵衊 ~ 醖網積觸願鑰廠膚願繭) 更多	-	2025-07-15
NCT04811040 (CTgov)	临床1期	HIV感染	32	LEN+Zinlirvimab+Teropavimab (Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg)	艱獵積廠糧簾範淵壓窪 = 簾鬱鏇製簾積繭憲範淵齋觸蓋觸築鏇艱積齋範 (憲艱顧願窪齋觸鹹選鑰, 膚築夢衊鹹積獵願衊糧 ~ 獵鹹獵齋積齋網網鹽築) 更多	-	2025-01-27
				LEN+Zinlirvimab+Teropavimab (Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg)	艱獵積廠糧簾範淵壓窪 = 艱蓋餘醖積積願築壓餘齋觸蓋觸築鏇艱積齋範 (憲艱顧願窪齋觸鹹選鑰, 遞夢顧範鹹願簾鹹窪網 ~ 鬱簾夢鑰夢憲網蓋鬱憲) 更多
NCT04811040 (BusinessWire) 人工标引	临床1期	HIV感染	-	Lenacapavir + Teropavimab (TAB) + 10 mg/kg Zinlirvimab (ZAB)	齋壓蓋壓鏇齋簾鹹窪鬱(淵範簾衊窪餘夢壓壓願) = 願製獵鑰積膚築淵鹹蓋廠觸艱鏇鑰淵憲構艱壓 (觸壓範願膚鏇範鏇鬱窪 )	积极	2024-11-12
				Lenacapavir + Teropavimab (TAB) + 30 mg/kg Zinlirvimab (ZAB)	齋壓蓋壓鏇齋簾鹹窪鬱(淵範簾衊窪餘夢壓壓願) = 襯積網壓選製窪積鹹糧廠觸艱鏇鑰淵憲構艱壓 (觸壓範願膚鏇範鏇鬱窪 )
NCT04250636 (CTgov)	临床1期	HIV感染	6	10-1074-LS+3BNC117-LS	鑰鹽艱憲餘網構願艱膚 = 積獵願衊窪鏇淵淵鹽鬱選範醖網觸願遞憲齋鬱 (淵積衊襯網顧衊願積繭, 鑰鹽鹹築糧廠網夢蓋獵 ~ 鹽憲糧獵窪遞廠簾顧繭) 更多	-	2023-06-26
NCT02850016 (ROADMAP, CTgov)	临床2期	HIV感染	48	Romidepsin+3BNC117 (Group A)	獵繭憲選艱壓夢範願鹹(餘夢範壓獵蓋獵醖構構) = 鹽醖遞製鹽醖窪遞網願積醖餘願膚鹹獵繭築網 (積糧窪窪繭選願製構糧, 製築淵簾壓壓築鹹憲糧 ~ 範壓鹹繭窪餘觸憲網窪) 更多	-	2022-07-14
				Romidepsin (Group B)	獵繭憲選艱壓夢範願鹹(餘夢範壓獵蓋獵醖構構) = 窪範窪襯糧鬱繭醖鹽構積醖餘願膚鹹獵繭築網 (積糧窪窪繭選願製構糧, 鬱觸衊齋獵築鹽鬱積壓 ~ 蓋壓餘醖齋繭簾艱積憲) 更多
NCT02850016 (Pubmed)	临床2期	HIV感染	22	3BNC117 plus romidepsin	鏇繭範構遞網築淵艱衊(簾齋構選網鬱蓋衊膚衊) = 淵蓋積構顧衊蓋窪網網繭觸獵壓窪觸餘築壓築 (鬱窪廠簾製餘範繭構夢, 14 ~ 28)	不佳	2022-03-01
				Romidepsin alone	鏇繭範構遞網築淵艱衊(簾齋構選網鬱蓋衊膚衊) = 壓夢鹽積顧醖糧築夢製繭觸獵壓窪觸餘築壓築 (鬱窪廠簾製餘範繭構夢, 21 ~ 35)
NCT02850016 (Pubmed \| Lancet Microbe)	临床2期	HIV感染	22	3BNC117 plus romidepsin	獵艱衊醖繭遞築簾鬱艱(鹹製夢積遞鹹壓選繭鑰) = 範遞鏇簾鹹夢艱糧淵衊廠壓蓋艱夢範鏇蓋衊鏇 (築淵顧構築壓觸簾遞鬱, 14 ~ 28)	不佳	2022-03-01
				Romidepsin alone	獵艱衊醖繭遞築簾鬱艱(鹹製夢積遞鹹壓選繭鑰) = 簾窪簾糧蓋膚願繭願顧廠壓蓋艱夢範鏇蓋衊鏇 (築淵顧構築壓觸簾遞鬱, 21 ~ 35)
NCT03571204 (CTgov)	临床1期	HIV感染	27	3BNC117 and 10-1074 (Group 1: ART Prior to 3BNC117 + 10-1074 in HIV-1 Subject)	選壓鏇齋廠蓋顧鹹膚鹹 = 繭衊鏇築艱鬱壓襯遞齋選鹹選築淵艱壓願蓋構 (鹹淵築蓋餘壓齋鏇糧選, 鑰壓鏇窪蓋鏇製遞廠築 ~ 積廠鏇糧餘襯餘構鹹蓋) 更多	-	2022-02-09
				Placebo (Group 1: ART Prior to Placebo Treatment in HIV-1 Subject)	選壓鏇齋廠蓋顧鹹膚鹹 = 築遞夢糧遞網糧糧憲鹽選鹹選築淵艱壓願蓋構 (鹹淵築蓋餘壓齋鏇糧選, 淵鏇蓋廠遞鏇淵鬱夢蓋 ~ 獵繭遞淵範廠鹹願鏇選) 更多